

Serial No.: 09/692,401

- 2 -

Art Unit: 1644

binds a HLA class I molecule and which consists essentially of the amino acid sequence of SEQ ID NO:6 with one amino acid addition, substitution or deletion.

C1
2.(twice amended) An isolated MAGE-A12 HLA class I-binding peptide consisting essentially of the amino acid sequence of SEQ ID NO:4, or a functional variant thereof which binds a HLA class I molecule and which consists essentially of the amino acid sequence of SEQ ID NO:4 with one amino acid addition, substitution or deletion.

3.(twice amended) An isolated MAGE-A12 HLA class I-binding peptide consisting essentially of the amino acid sequence of SEQ ID NO:5, or a functional variant thereof which binds a HLA class I molecule and which consists essentially of the amino acid sequence of SEQ ID NO:5 with one amino acid addition, substitution or deletion.

4.(twice amended) An isolated MAGE-A12 HLA class I binding peptide consisting essentially of a fragment of the amino acid sequence of SEQ ID NO:2 which binds HLA Cw*07, or a functional variant thereof which consists essentially of the fragment of the amino acid sequence of SEQ ID NO:2 with one amino acid addition, substitution or deletion, wherein the functional variant binds HLA Cw*07.

Please add the following new claims:

C2
58.(new) The isolated MAGE-A12 HLA class I-binding peptide of claim 1 wherein the isolated peptide is non-hydrolyzable.

59.(new) The isolated MAGE-A12 HLA class I-binding peptide of claim 58 wherein the isolated peptide is selected from the group consisting of peptides comprising D-amino acids, peptides comprising a -psi[CH₂NH]-reduced amide peptide bond, peptides comprising a -psi[COCH₂]-ketomethylene peptide bond, peptides comprising a -psi[CH(CN)NH]-(cyanomethylene)amino peptide bond, peptides comprising a -psi[CH₂CH(OH)]-hydroxyethylene peptide bond, peptides comprising a -psi[CH₂O]-peptide bond, and peptides comprising a -psi[CH₂S]-thiomethylene peptide bond.

Serial No.: 09/692,401

- 3 -

Art Unit: 1644

60.(new) The isolated MAGE-A12 HLA class I-binding peptide of claim 2 wherein the isolated peptide is non-hydrolyzable.

61.(new) The isolated MAGE-A12 HLA class I-binding peptide of claim 60 wherein the isolated peptide is selected from the group consisting of peptides comprising D-amino acids, peptides comprising a -psi[CH₂NH]-reduced amide peptide bond, peptides comprising a -psi[COCH₂]-ketomethylene peptide bond, peptides comprising a -psi[CH(CN)NH]-(cyanomethylene)amino peptide bond, peptides comprising a -psi[CH₂CH(OH)]-hydroxyethylene peptide bond, peptides comprising a -psi[CH₂O]-peptide bond, and peptides comprising a -psi[CH₂S]-thiomethylene peptide bond.

62.(new) The isolated MAGE-A12 HLA class I-binding peptide of claim 3 wherein the isolated peptide is non-hydrolyzable.

C2
63.(new) The isolated MAGE-A12 HLA class I-binding peptide of claim 62 wherein the isolated peptide is selected from the group consisting of peptides comprising D-amino acids, peptides comprising a -psi[CH₂NH]-reduced amide peptide bond, peptides comprising a -psi[COCH₂]-ketomethylene peptide bond, peptides comprising a -psi[CH(CN)NH]-(cyanomethylene)amino peptide bond, peptides comprising a -psi[CH₂CH(OH)]-hydroxyethylene peptide bond, peptides comprising a -psi[CH₂O]-peptide bond, and peptides comprising a -psi[CH₂S]-thiomethylene peptide bond.

64.(new) The isolated MAGE-A12 HLA class I-binding peptide of claim 4 wherein the isolated peptide is non-hydrolyzable.

65.(new) The isolated MAGE-A12 HLA class I-binding peptide of claim 64 wherein the isolated peptide is selected from the group consisting of peptides comprising D-amino acids, peptides comprising a -psi[CH₂NH]-reduced amide peptide bond, peptides comprising a -psi[COCH₂]-ketomethylene peptide bond, peptides comprising a -psi[CH(CN)NH]-(cyanomethylene)amino peptide bond, peptides comprising a -

Serial No.: 09/692,401

- 4 -

Art Unit: 1644

psi[CH₂CH(OH)]-hydroxyethylene peptide bond, peptides comprising a -psi[CH₂O]-peptide bond, and peptides comprising a -psi[CH₂S]-thiomethylene peptide bond.

66.(new) A composition comprising the isolated MAGE-A12 HLA class I-binding peptide of claim 2 and an isolated HLA class I- or class II-binding peptide of a non-MAGE-A12 tumor antigen.

67.(new) A composition comprising the isolated MAGE-A12 HLA class I binding peptide of claim 3 and an isolated HLA class I- or class II-binding peptide of a non-MAGE-A12 tumor antigen.

68.(new) The composition of claim 7, wherein the MAGE-A12 HLA class I-binding peptide and the HLA class I- or class II-binding peptide of a non-MAGE-A12 tumor antigen are combined as a polytope polypeptide.

69.(new) The composition of claim 8, wherein the MAGE-A12 HLA class I-binding peptide and the HLA class I- or class II-binding peptide of a non-MAGE-A12 tumor antigen are combined as a polytope polypeptide.

70.(new) The composition of claim 66, wherein the MAGE-A12 HLA class I-binding peptide and the HLA class I- or class II-binding peptide of a non-MAGE-A12 tumor antigen are combined as a polytope polypeptide.

71.(new) The composition of claim 67, wherein the MAGE-A12 HLA class I-binding peptide and the HLA class I- or class II-binding peptide of a non-MAGE-A12 tumor antigen are combined as a polytope polypeptide.

72.(new) A vaccine composition comprising the polypeptide of claim 2 and a pharmaceutically acceptable carrier.